Inconsistent HIV reservoir dynamics and immune responses following anti-PD-1 therapy in cancer patients with HIV infection

Affiliations

¹ Division of Infectious Diseases, Johns Hopkins University School of Medicine, Baltimore, USA; Ragon Institute of MGH, MIT and Harvard, Massachusetts General Hospital, Cambridge, USA; Division of Infectious Diseases, Brigham and Women's Hospital, Boston, USA.
² Division of Experimental Medicine, University of California San Francisco, San Francisco, USA.
³ Ragon Institute of MGH, MIT and Harvard, Massachusetts General Hospital, Cambridge, USA; Biomedical Sciences Program, University of California San Francisco, San Francisco, USA.
⁴ Division of Infectious Diseases, Brigham and Women's Hospital, Boston, USA; INSERM Laboratoire de Microbiologie, Hôpital Saint Louis, Assistance Publique Hôpitaux de Paris, France.
⁵ Ragon Institute of MGH, MIT and Harvard, Massachusetts General Hospital, Cambridge, USA.
⁶ Division of Infectious Diseases, Brigham and Women's Hospital, Boston, USA.
⁷ Division of HIV, Infectious Diseases and Global Health, University of California San Francisco, San Francisco, USA.
⁸ Blood Systems Research Institute, San Francisco, USA.
⁹ Medical Oncology, University of California San Francisco, San Francisco, USA.
¹⁰ Medical Oncology, Dana-Farber Cancer Institute, Boston, USA.
¹¹ Division of Experimental Medicine, University of California San Francisco, San Francisco, USA. Electronic address: timothy.henrich@ucsf.edu.

E P Scully et al. Ann Oncol. 2018.

. 2018 Oct 1;29(10):2141-2142.

doi: 10.1093/annonc/mdy259.

¹ Division of Infectious Diseases, Johns Hopkins University School of Medicine, Baltimore, USA; Ragon Institute of MGH, MIT and Harvard, Massachusetts General Hospital, Cambridge, USA; Division of Infectious Diseases, Brigham and Women's Hospital, Boston, USA.
² Division of Experimental Medicine, University of California San Francisco, San Francisco, USA.
³ Ragon Institute of MGH, MIT and Harvard, Massachusetts General Hospital, Cambridge, USA; Biomedical Sciences Program, University of California San Francisco, San Francisco, USA.
⁴ Division of Infectious Diseases, Brigham and Women's Hospital, Boston, USA; INSERM Laboratoire de Microbiologie, Hôpital Saint Louis, Assistance Publique Hôpitaux de Paris, France.
⁵ Ragon Institute of MGH, MIT and Harvard, Massachusetts General Hospital, Cambridge, USA.
⁶ Division of Infectious Diseases, Brigham and Women's Hospital, Boston, USA.
⁷ Division of HIV, Infectious Diseases and Global Health, University of California San Francisco, San Francisco, USA.
⁸ Blood Systems Research Institute, San Francisco, USA.
⁹ Medical Oncology, University of California San Francisco, San Francisco, USA.
¹⁰ Medical Oncology, Dana-Farber Cancer Institute, Boston, USA.
¹¹ Division of Experimental Medicine, University of California San Francisco, San Francisco, USA. Electronic address: timothy.henrich@ucsf.edu.

No abstract available

Figures

1. Guihot A, Marcelin AG, Massiani MA. et al. Drastic decrease of the HIV reservoir in a patient treated with nivolumab for lung cancer. Ann Oncol 2018; 29(2): 517–518. - PubMed
1. Le Garff G, Samri A, Lambert-Niclot S. et al. Transient HIV-specific T cells increase and inflammation in an HIV-infected patient treated with nivolumab. AIDS 2017; 31(7): 1048–1051. - PubMed
1. Henrich TJ, Hatano H, Bacon O. et al. HIV-1 persistence following extremely early initiation of antiretroviral therapy (ART) during acute HIV-1 infection: an observational study. PLoS Med 2017; 14: e1002417. - PMC - PubMed
1. Naidoo J, Page DB, Li BT. et al. Toxicities of the anti-PD-1 and anti-PD-L1 immune checkpoint antibodies. Ann Oncol 2015; 26: 2375–2391. - PMC - PubMed